What Researchers Did
Researchers reviewed the complex interplay of factors contributing to the pathogenesis and pathology of COVID-associated mucormycosis (CAM).
What They Found
They found a sudden increase in COVID-associated mucormycosis (CAM), especially in India during the second wave of the pandemic, driven by factors like hyperglycemia, acidosis, and lowered host defenses. The review highlighted the high background prevalence of diabetes mellitus in India, which, combined with COVID-19 itself and corticosteroid use, contributes to hyperglycemia and increased susceptibility.
What This Means for Canadian Patients
Canadian patients with diabetes, especially those with uncontrolled blood sugar, who contract COVID-19 and receive corticosteroids, should be monitored for signs of mucormycosis. Early recognition and management of risk factors like hyperglycemia and acidosis are crucial to prevent this severe fungal infection.
Canadian Relevance
This review does not have a direct Canadian connection, as it primarily focuses on the surge of COVID-associated mucormycosis observed in India.
Study Limitations
As a review article, this study synthesizes existing literature and does not present new primary research data or specific patient outcomes.